[go: up one dir, main page]

MA39901A - Antagonistes de mglu2/3 pour le traitement de troubles des facultés intellectuelles - Google Patents

Antagonistes de mglu2/3 pour le traitement de troubles des facultés intellectuelles

Info

Publication number
MA39901A
MA39901A MA039901A MA39901A MA39901A MA 39901 A MA39901 A MA 39901A MA 039901 A MA039901 A MA 039901A MA 39901 A MA39901 A MA 39901A MA 39901 A MA39901 A MA 39901A
Authority
MA
Morocco
Prior art keywords
treatment
mglu2
intellectual disabilities
antagonists
relates
Prior art date
Application number
MA039901A
Other languages
English (en)
Inventor
Theresa M Ballard
Mcarthur Silvia Gatti
Michael Saxe
Juergen Wichmann
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA39901A publication Critical patent/MA39901A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une nouvelle utilisation médicale de certains composés chimiques et des compositions pharmaceutiques les contenant. La présente invention concerne des composés qui sont des modulateurs allostériques négatifs de mglu2/3 pour l'utilisation dans le traitement de troubles des facultés intellectuelles. Dans un autre aspect, l'invention concerne une composition pharmaceutique pour utilisation dans le traitement de troubles des facultés intellectuelles, comprenant un composé selon l'invention et un véhicule pharmaceutiquement acceptable.
MA039901A 2014-04-23 2015-04-20 Antagonistes de mglu2/3 pour le traitement de troubles des facultés intellectuelles MA39901A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14165632 2014-04-23

Publications (1)

Publication Number Publication Date
MA39901A true MA39901A (fr) 2017-03-01

Family

ID=50513799

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039901A MA39901A (fr) 2014-04-23 2015-04-20 Antagonistes de mglu2/3 pour le traitement de troubles des facultés intellectuelles

Country Status (12)

Country Link
US (4) US20170035767A1 (fr)
EP (1) EP3134089A2 (fr)
JP (1) JP2017513844A (fr)
KR (1) KR20160143853A (fr)
CN (2) CN110483525A (fr)
AR (1) AR100151A1 (fr)
BR (1) BR112016021727A2 (fr)
CA (1) CA2943877A1 (fr)
MA (1) MA39901A (fr)
MX (1) MX2016013711A (fr)
RU (1) RU2016144702A (fr)
WO (1) WO2015162076A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202106872D0 (en) * 2021-05-13 2021-06-30 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1224174T3 (da) 1999-10-15 2004-01-26 Hoffmann La Roche Benzodiazepinderivater
NZ518037A (en) 1999-10-15 2004-04-30 F Benzodiazepine derivatives useful as metabotropic glutamate receptors
HRP20030792A2 (en) * 2001-04-12 2005-10-31 F. Hoffmann - La Roche Ag DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
KR100566178B1 (ko) 2001-04-12 2006-03-29 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ2 길항물질 Ｉ로서의디하이드로-벤조[ｂ][1,4]디아제핀-2-온 유도체
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
DE10330447A1 (de) 2003-07-05 2005-02-10 Daimlerchrysler Ag Vorrichtung und Verfahren zum Vergleich von Bauteilen
PL1651234T3 (pl) 2003-07-25 2008-02-29 Hoffmann La Roche Kompozycja antagonisty mGluR2 i inhibitora AChE do leczenia ostrych i/lub przewlekłych zaburzeń neurologicznych
MXPA06014809A (es) 2004-06-21 2007-02-12 Hoffmann La Roche Derivados de pirazol-pirimidina.
JP4708438B2 (ja) 2005-02-11 2011-06-22 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのピラゾロピリミジン誘導体
AU2006226669B2 (en) * 2005-03-23 2011-12-08 F. Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mGluR2 antagonists
AU2006298829B2 (en) 2005-09-27 2011-03-03 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists
KR20120034772A (ko) * 2006-03-29 2012-04-12 에프. 호프만-라 로슈 아게 Ｍｇｌｕｒ2 길항물질로서의 피리딘 및 피리미딘 유도체
US8012986B2 (en) 2007-04-02 2011-09-06 Hoffmann-La Roche Inc. Pyridine and pyrimidine derivatives as MGLUR2 antagonists
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
EP2666775A1 (fr) * 2012-05-21 2013-11-27 Domain Therapeutics Pyrazoloquinazolinones et pyrroloquinazolinones substitués en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate du groupe II
AR093077A1 (es) * 2012-10-23 2015-05-20 Hoffmann La Roche ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS

Also Published As

Publication number Publication date
US20250017937A1 (en) 2025-01-16
US20170035767A1 (en) 2017-02-09
RU2016144702A (ru) 2018-05-24
CA2943877A1 (fr) 2015-10-29
BR112016021727A2 (pt) 2017-08-15
US20190343839A1 (en) 2019-11-14
JP2017513844A (ja) 2017-06-01
EP3134089A2 (fr) 2017-03-01
WO2015162076A2 (fr) 2015-10-29
CN106132966A (zh) 2016-11-16
WO2015162076A3 (fr) 2015-12-10
CN110483525A (zh) 2019-11-22
AR100151A1 (es) 2016-09-14
US20180235971A1 (en) 2018-08-23
KR20160143853A (ko) 2016-12-14
MX2016013711A (es) 2017-01-13

Similar Documents

Publication Publication Date Title
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
MY187540A (en) Compounds active towards bromodomains
PH12015502615B1 (en) Chemical compounds
PH12016501570B1 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
NZ737399A (en) Ccr2 modulators
PH12016501791A1 (en) Muscarinic receptor agonists
MX2015004604A (es) Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas.
TW201613864A (en) Novel compounds
IL312218B2 (en) Preparations for oral administration of active ingredients
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX362879B (es) Usos novedosos.
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
PH12016500124A1 (en) Via antagonists to treat phase shift sleep disorders
WO2015001541A3 (fr) Composition de film pharmaceutique
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
MX2016013711A (es) Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
HK40101429A (en) Formulations for oral administration of active agents
HK40101653A (en) Formulations for oral administration of active agents